Literature DB >> 22674711

Radiofrequency ablation combined with transcatheter arterial embolisation in rabbit liver: investigation of the ablation zone according to the time interval between the two therapies.

I J Lee1, Y I Kim, K W Kim, D H Kim, I Ryoo, M W Lee, J W Chung.   

Abstract

OBJECTIVES: This study was designed to evaluate the extent of the radiofrequency ablation zone in relation to the time interval between transcatheter arterial embolisation (TAE) and radiofrequency ablation (RFA) and, ultimately, to determine the optimal strategy of combining these two therapies for hepatocellular carcinoma.
METHODS: 15 rabbits were evenly divided into three groups: Group A was treated with RFA alone; Group B was treated with TAE immediately followed by RFA; and Group C was treated with TAE followed by RFA 5 days later. All animals underwent perfusion CT (PCT) scans immediately after RFA. Serum liver transaminases were measured to evaluate acute liver damage. Animals were euthanised for pathological analysis of ablated tissues 10 days after RFA. Non-parametric analyses were conducted to compare PCT indices, the RFA zone and liver transaminase levels among the three experimental groups.
RESULTS: Group B showed a significantly larger ablation zone than the other two groups. Arterial liver perfusion and hepatic perfusion index represented well the perfusion decrease after TAE on PCT. Although Group B showed the most elevated liver transaminase levels at 1 day post RFA, the enzymes decreased to levels that were not different from the other groups at 10 days post-RFA.
CONCLUSIONS: When combined TAE and RFA therapy is considered, TAE should be followed by RFA as quickly as possible, as it can be performed safely without serious hepatic deterioration, despite the short interval between the two procedures.

Entities:  

Mesh:

Year:  2012        PMID: 22674711      PMCID: PMC3500822          DOI: 10.1259/bjr/90024696

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  26 in total

1.  The role of perfusion CT as a follow-up modality after transcatheter arterial chemoembolization: an experimental study in a rabbit model.

Authors:  Seung Hong Choi; Jin Wook Chung; Hyo-Cheol Kim; Hyo-Choel Kim; Jin Ho Baek; Chang Min Park; Suryoung Jun; Min Uk Kim; Eun Sun Lee; Hye Rim Cho; Hwan Jun Jae; Whal Lee; Jae Hyung Park
Journal:  Invest Radiol       Date:  2010-07       Impact factor: 6.016

2.  Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data.

Authors:  C S Patlak; R G Blasberg; J D Fenstermacher
Journal:  J Cereb Blood Flow Metab       Date:  1983-03       Impact factor: 6.200

3.  Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents.

Authors:  K Takayasu; Y Shima; Y Muramatsu; N Moriyama; T Yamada; M Makuuchi; H Hasegawa; S Hirohashi
Journal:  Radiology       Date:  1987-05       Impact factor: 11.105

4.  Comparison between transauricular and transfemoral arterial access for hepatic artery angiography in a rabbit model.

Authors:  Il Soo Chang; Min Woo Lee; Young Il Kim; Seung Hong Choi; Hyo-Cheol Kim; Yo Won Choi; Chang Jin Yoon; Sung Wook Shin; Hyo K Lim
Journal:  J Vasc Interv Radiol       Date:  2011-03-03       Impact factor: 3.464

5.  Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis.

Authors:  Kenichi Takayasu; Shigeki Arii; Iwao Ikai; Masatoshi Kudo; Yutaka Matsuyama; Masamichi Kojiro; Masatoshi Makuuchi
Journal:  AJR Am J Roentgenol       Date:  2010-03       Impact factor: 3.959

6.  Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue-long-term prospective study.

Authors:  E Caturelli; D A Siena; S Fusilli; M R Villani; G Schiavone; M Nardella; S Balzano; F Florio
Journal:  Radiology       Date:  2000-04       Impact factor: 11.105

7.  Treatment of hepatocellular carcinoma with radiofrequency ablation: radiologic-histologic correlation during follow-up periods.

Authors:  Manabu Morimoto; Kazuya Sugimori; Kazuhito Shirato; Atsushi Kokawa; Naohiko Tomita; Takafumi Saito; Noriko Tanaka; Akinori Nozawa; Masamichi Hara; Hisahiko Sekihara; Hiroshi Shimada; Toshio Imada; Katsuaki Tanaka
Journal:  Hepatology       Date:  2002-06       Impact factor: 17.425

8.  Single-step therapy -- feasibility and safety of simultaneous transarterial chemoembolization and radiofrequency ablation for hepatic malignancies.

Authors:  Cosmo Gadaleta; Annamaria Catino; Girolamo Ranieri; Vito Fazio; Gennaro Gadaleta-Caldarola; Antonio Cramarossa; Francesco Armenise; Eugenio Canniello; Gianluca Vinciarelli; Giuseppe Laricchia; Vittorio Mattioli
Journal:  In Vivo       Date:  2009 Sep-Oct       Impact factor: 2.155

9.  Perfusion CT: noninvasive surrogate marker for stratification of pancreatic cancer response to concurrent chemo- and radiation therapy.

Authors:  Mi-Suk Park; Ernst Klotz; Myeong-Jin Kim; Si Young Song; Seung Woo Park; Seung-Whan Cha; Joon Soek Lim; Jinsil Seong; Jae Bok Chung; Ki Whang Kim
Journal:  Radiology       Date:  2008-11-04       Impact factor: 11.105

10.  Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial.

Authors:  Bao-Quan Cheng; Chong-Qi Jia; Chun-Tao Liu; Wei Fan; Qing-Liang Wang; Zong-Li Zhang; Cui-Hua Yi
Journal:  JAMA       Date:  2008-04-09       Impact factor: 56.272

View more
  5 in total

1.  Multiple imaging modality-guided radiofrequency ablation combined with transarterial chemoembolization for hepatocellular carcinoma in special locations.

Authors:  Bo-Shuai Yang; Ling-Xiao Liu; Min Yuan; Yi-Bin Hou; Qing-Tao Li; Su Zhou; Yu-Xin Shi; Bu-Lang Gao
Journal:  Diagn Interv Radiol       Date:  2020-03       Impact factor: 2.630

Review 2.  Ablation plus Transarterial Embolic Therapy for Hepatocellular Carcinoma Larger than 3 cm: Science, Evidence, and Future Directions.

Authors:  Andrew R Lewis; Carlos A Padula; J Mark McKinney; Beau B Toskich
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

3.  Combined transarterial chemoembolization and radiofrequency ablation for subphrenic versus nonsubphrenic hepatocellular carcinoma: a propensity score matched study.

Authors:  Jun Gon Kim; Sung Ki Cho; Dongho Hyun; Sung Wook Shin; Kwang Bo Park; Hong Suk Park; Sung Wook Choo; Young Soo Do; Sook-Young Woo; Sun-Young Baek
Journal:  Abdom Radiol (NY)       Date:  2021-09-28

4.  Image-Based Analysis of Tumor Localization After Intra-Arterial Delivery of Technetium-99m-Labeled SPIO Using SPECT/CT and MRI.

Authors:  In Joon Lee; Ji Yong Park; Young-Il Kim; Yun-Sang Lee; Jae Min Jeong; Jaeil Kim; Euishin Edmund Kim; Keon Wook Kang; Dong Soo Lee; Seonji Jeong; Eun Jeong Kim; Young Il Kim; Jin Wook Chung
Journal:  Mol Imaging       Date:  2017-01-01       Impact factor: 4.488

5.  Dual switching monopolar radiofrequency ablation using a separable clustered electrode: comparison with consecutive and switching monopolar modes in ex vivo bovine livers.

Authors:  Jeong-Hee Yoon; Jeong Min Lee; Joon Koo Han; Byung Ihn Choi
Journal:  Korean J Radiol       Date:  2013-05-02       Impact factor: 3.500

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.